Pfizer (PFE) Other Accumulated Expenses (2009 - 2026)

Pfizer (PFE) has reported Other Accumulated Expenses for 17 consecutive years, with $20.1 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Accumulated Expenses changed 0.46% year-over-year to $20.1 billion; the TTM figure through Mar 2026 stood at $20.1 billion (changed 0.46% YoY), while the FY2025 annual figure was $19.4 billion, down 1.46% from the prior year.
• Other Accumulated Expenses grew to $20.1 billion in Q1 2026 per PFE's latest filing, from $19.4 billion in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $24.6 billion in Q2 2022 and bottomed at $16.1 billion in Q3 2023.
• Historically, Other Accumulated Expenses has averaged $20.0 billion across 5 years, with a median of $19.9 billion in 2024.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses soared 92.08% — and 2023, when it plunged 32.49%.
• Pfizer's Other Accumulated Expenses stood at $22.6 billion in 2022, then slipped by 9.0% to $20.5 billion in 2023, then decreased by 3.98% to $19.7 billion in 2024, then dropped by 1.46% to $19.4 billion in 2025, then rose by 3.48% to $20.1 billion in 2026.
• Business Quant data shows PFE's Other Accumulated Expenses at $20.1 billion in Q1 2026, $19.4 billion in Q4 2025, and $19.5 billion in Q3 2025.